Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114965) titled 'A clinical study of carboplatin/albumin paclitaxel combined with PD-L1 inhibitor as neoadjuvant therapy for resectable Cervical Esophageal Squamous Cell Carcinoma' on Dec. 19, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Cervical Esophageal Squamous Cell Carcinoma
Intervention:
Trial group:Serplulimab: Intravenous injection, fixed dose of 300 mg, intravenous injection, Day 1, repeated every 3 weeks
Albumin-bound paclitaxel: 130 mg/m^2 on Day 1 and Day 8, repeated every 3 weeks
Recruitment Status: Not Recruiting
Phase: 2
Date of Fi...